Oct 17, 2016 11:00 am UTC| Business
WEST PALM BEACH, Fla., Oct. 17, 2016 -- Platform Specialty Products Corporation (NYSE:PAH) ("Platform"), a global specialty chemicals company, today announced that it has successfully completed the repricing, extension...
Idaho Independent Bank Announces 2016 Third Quarter and Year-to-Date Results
Oct 17, 2016 11:00 am UTC| Business
COEUR D’ALENE, Idaho, Oct. 17, 2016 -- Jack W. Gustavel, Chairman and Chief Executive Officer of Idaho Independent Bank (“IIB” or the “Bank”) (OTC BB:IIBK), announced IIB’s unaudited, consolidated financial results for...
Oct 17, 2016 11:00 am UTC| Business
SAN DIEGO, Oct. 17, 2016 -- Kratos Defense Security Solutions, Inc. (NASDAQ:KTOS), a leading National Security Solutions provider, announced today that it has been awarded a $12.6 million contract with Defense...
Snyder’s-Lance to Report Third Quarter Results on November 7, 2016
Oct 17, 2016 11:00 am UTC| Business
CHARLOTTE, N.C., Oct. 17, 2016 -- Snyder’s-Lance, Inc. (Nasdaq:LNCE) announced today that it will release its third quarter 2016 results before the market opens on Monday, November 7, 2016, followed by a conference call...
Advanced Accelerator Applications Announces Positive EMA Opinion on Application for SomaKit TOC
Oct 17, 2016 11:00 am UTC| Business
SAINT-GENIS-POUILLY, France, Oct. 17, 2016 -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (“AAA” or “the Company”), an international specialist in molecular nuclear medicine, today announced that the European...
Michael Aldridge Joins Codexis as Senior Vice President, Corporate & Strategic Development
Oct 17, 2016 11:00 am UTC| Business
REDWOOD CITY, Calif., Oct. 17, 2016 -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that Michael Aldridge has joined the company as Senior Vice President, Corporate Strategic...
Zynerba Provides Clinical Update for Lead Development Candidates – ZYN001 and ZYN002
Oct 17, 2016 10:59 am UTC| Business
Phase 1 clinical trial for ZYN001 is expected to begin in 1H17 Topline results for three Phase 2 clinical trials for ZYN002 are on track for 1H17 DEVON, Pa., Oct. 17, 2016 -- Zynerba Pharmaceuticals, Inc....